Top Markets
Coin of the day
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
株式のランク #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$4.94K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Arno Therapeutics, Inc. (ARNI)

カテゴリー

Arno Therapeutics, Inc.(ARNI)のP/E比率
2026 時点のP/E比率 TTM 0
Arno Therapeutics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Arno Therapeutics, Inc. の P/E 比率の履歴(2026 〜 2026)
各年末のP/E比率
P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
28.05 -
US
31.14 -
NL
- -
CH
19.30 -
BE
- -
KR
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。